Physical recovery Other
Conditions
Interventions
Study Design Description (English Version)
Interventional, randomized controlled trial (RCT) designed to evaluate the adaptive effects of various recovery strategies in individuals with differing leve
Sponsors
Provita Medical centre
Eligibility
Sex/Gender
All
Age
18 Years to 45 Years
Inclusion criteria
Inclusion criteria: 1. Age between 18 and 45 years. 2. No contraindications to physical activity – confirmed by a physician. 3. Valid medical clearance for participation in physical training, issued within the past 6 months. 4. Regular physical training history, defined as: 4.1. At least 2 training sessions per week for a minimum of 1 year for amateur participants. 4.2. At least 6 training sessions per week for a minimum of 5 years for professional athletes, as classified according to the McKay et al. (2022) system. 5. Completed health screening questionnaire with no exclusionary findings. 6. Written informed consent to participate, signed voluntarily after being informed of the study protocol, risks, and benefits.
Exclusion criteria
Exclusion criteria: 1. Cardiovascular diseases or any medical contraindications to physical exertion. 2. Recent musculoskeletal injuries that limit activity and occurred within 3 months prior to study initiation. 3. History of orthopedic surgery involving the musculoskeletal system within the past 9 months. 4. Active skin diseases or unidentified skin lesions at the intended site of intervention (e.g., for compression devices). 5. Poor general health, excessive fatigue, or symptoms of sports-related depression. 6. Use of substances or medications affecting hemodynamics or masking physiological recovery markers, including: 6.1. Beta-blockers (e.g., metoprolol, bisoprolol) 6.2. Vasodilators (e.g., nitrates, calcium channel blockers) 6.3. Diuretics (e.g., furosemide, hydrochlorothiazide) 6.4. ACE inhibitors and sartans (e.g., enalapril, losartan) 6.5. Anticoagulants (e.g., heparins, NOACs such as apixaban, rivaroxaban) 7. Use of performance-enhancing drugs (doping substances). 8. Refusal to provide informed consent or voluntary withdrawal at any stage of the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| At baseline, after 2 weeks of intervention, and after 8 weeks. For long-term follow-up groups, we will also conduct measurements at 6 months: 1. Biochemical markers (measured in blood serum): 1.1. Creatine kinase (CK) – measured in U/L; spectrophotometric ELISA; standard laboratory method; Poland, 2023. 1.2. C-reactive protein (CRP) – measured in mg/L; immunoturbidimetric assay; Poland, 2023. 1.3. Lactate dehydrogenase (LDH) – measured in U/L; spectrophotometric assay; Poland, 2023. 1.4. Interleukin-6 (IL-6) – measured in pg/mL; ELISA; Poland, 2023. 1.5. Tumor necrosis factor alpha (TNF-a) – measured in pg/mL; ELISA; Poland, 2023. 1.6. Cortisol – measured in µg/dL; immunoassay; Poland, 2023. 1.7. Testosterone – measured in ng/dL; immunoassay; Poland, 2023. 2. Mechanical and biomechanical measures: 2.1. Muscle tension, stiffness, and elasticity – measured in N/m and milliseconds; assessed using MyotonPRO (Myoton AS), Estonia, 2021. 2.2. Reactive Strength Index (RSI) – measured in m/s; assessed with ForceDecks (Vald Performance), Germany, 2020. 2.3. Maximal voluntary contraction (MVC) – measured in Newtons (N); assessed using K-Force (Kinvent), Italy, 2023. 2.4. Tissue perfusion – measured in Perfusion Units (PU); evaluated using Laser Doppler Flowmeter (Perimed), Sweden, 2004. 2.5. Pressure pain threshold (PPT) – measured in kg/cm²; assessed with Algometer FPIX 25 (Medoc), USA, 2021. 2.6. Electromyographic activity (EMG) – measured in µV; recorded using TruScan EMG (Deymed), Germany, 2022. 2.7. Range of motion (ROM) – measured in degrees (°); assessed using Baseline Inclinometer, Italy, 2020. 2.8. Body composition (fat percentage, muscle mass) – measured in %; evaluated using Accuniq BC720, South Korea, 2021. | — |
Secondary
| Measure | Time frame |
|---|---|
| At baseline, after 2 weeks of intervention, and after 8 weeks. For long-term follow-up groups, we will also conduct measurements at 6 months: 1. Psychometric scales and questionnaires: 1.1. TQR (Total Quality Recovery 0–20 scale) 1.2. Subjective fatigue – assessed using the Borg Rating of Perceived Exertion Scale (6–20 points); international tool. 1.3. Perceived recovery – assessed using the TQR (Total Quality Recovery) Scale (6–20 points); international tool. 1.4. Pain intensity – assessed using the RNS Pain Scale (0–10 points); validated version used in Poland. 2. Maximal voluntary contraction (MVC) – measured in Newtons (N); evaluated using Kinvent K-Force (Kinvent), Italy, 2023. | — |
Countries
Poland
Contacts
Public ContactRobert TrybulskI
Outcome results
None listed